| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1061 | 2021 |
| Clinical features and management of human monkeypox: a retrospective observational study in the UK H Adler, S Gould, P Hine, LB Snell, W Wong, CF Houlihan, JC Osborne, ... The Lancet Infectious Diseases 22 (8), 1153-1162, 2022 | 1007 | 2022 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 804 | 2022 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 759 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 671 | 2021 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
| Late Ebola virus relapse causing meningoencephalitis: a case report M Jacobs, A Rodger, DJ Bell, S Bhagani, I Cropley, A Filipe, RJ Gifford, ... The Lancet 388 (10043), 498-503, 2016 | 364 | 2016 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 338 | 2021 |
| ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ... Molecular Therapy 20 (12), 2355-2368, 2012 | 246 | 2012 |
| Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors SH Sheehy, CJA Duncan, SC Elias, S Biswas, KA Collins, GA O'Hara, ... PloS one 7 (2), e31208, 2012 | 192 | 2012 |
| Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant P Elliott, D Haw, H Wang, O Eales, CE Walters, KEC Ainslie, C Atchison, ... Science 374 (6574), eabl9551, 2021 | 115 | 2021 |
| Cytochrome P450 2B6 516G→ T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population TW Mahungu, CJ Smith, F Turner, D Egan, M Youle, MA Johnson, S Khoo, ... HIV medicine 10 (5), 310-317, 2009 | 91 | 2009 |
| HIV as a chronic disease TW Mahungu, AJ Rodger, MA Johnson Clinical Medicine 9 (2), 125, 2009 | 80 | 2009 |
| Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals A Schipani, C Wyen, T Mahungu, H Hendra, D Egan, M Siccardi, ... Journal of antimicrobial chemotherapy 66 (6), 1332-1339, 2011 | 72 | 2011 |
| The impact of viral mutations on recognition by SARS-CoV-2 specific T cells TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ... Iscience 24 (11), 2021 | 62 | 2021 |
| Decline in hepatitis C virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: progress to HCV microelimination in the United Kingdom? LJ Garvey, GS Cooke, C Smith, C Stingone, I Ghosh, S Dakshina, L Jain, ... Clinical Infectious Diseases 72 (2), 233-238, 2021 | 59 | 2021 |
| Autoimmunity and HIV R Stratton, G Slapak, T Mahungu, S Kinloch-de Loes Current opinion in infectious diseases 22 (1), 49-56, 2009 | 57 | 2009 |
| Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics CY Mason, T Kanitkar, CJ Richardson, M Lanzman, Z Stone, T Mahungu, ... Journal of Antimicrobial Chemotherapy 76 (5), 1323-1331, 2021 | 53 | 2021 |
| The impact of pharmacogenetics on HIV therapy TW Mahungu, MA Johnson, A Owen, DJ Back International journal of STD & AIDS 20 (3), 145-151, 2009 | 37 | 2009 |
| SARS-CoV-2 lineage B. 1.1. 7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study O Stirrup, F Boshier, C Venturini, JA Guerra-Assunção, A Alcolea-Medina, ... BMJ open respiratory research 8 (1), e001029, 2021 | 36 | 2021 |
